GU Cancers 2021 | Key updates in bladder cancer from ASCO GU 2021
Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights from ASCO GU 2021, in particular discussing the Phase III CheckMate 274 trial (NCT02632409) investigating nivolumab versus placebo in patients with high-risk muscle invasive urothelial carcinoma (MIUC) who have undergone radical surgery. The trial found that nivolumab improved disease-free survival (DFS) versus placebo in both randomized patients and patients with PD-L1 expression over 1%. Dr Sonpavde also outlines the Phase III AMBASSADOR trial (NCT03244384) evaluating pembrolizumab after surgery for MIUC, a retrospective analysis of the results of the Phase III IMvigor010 trial (NCT02450331) investigating atezolizumab in MIUC, and the Phase II RETAIN BLADDER trial (NCT02710734) of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer. Finally, Dr Sonpavde discusses the results of the Phase II/III QUILT-3.032 trial (NCT03022825) of a IL-15 superagonist, N-803, with BCG for the treatment of non muscle invasive bladder cancer that is unresponsive to BCG. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Guru Sonpavde, MD, has participated in advisory boards for BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, AstraZeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Immunomedics/Gilead, Scholar Rock and G1 Therapeutics; has received research support from Sanofi, AstraZeneca, Immunomedics/Gilead, QED, Predicine and BMS; has had travel costs reimbursed by BMS and AstraZeneca; has received speakers fees from Physicians Education Resource (PER), Onclive, Research to Practice and Medscape; has received writing fees from Uptodate and is Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; and has participated in unpaid steering committees of trials or studies with BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics, and in paid steering committees of trials or studies with AstraZeneca, EMD Serono and Debiopharm.
